Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.

You may also be interested in...



Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says

The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.

Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says

The deputy commissioner reiterates that the agency has not become risk averse when it comes to approvals, however.

Vioxx Litigation May Freeze Class-Wide Drug Development, AEI Scholar Calfee Suggests

Former FDA Chief Counsel Troy says Merck’s strategy to defend each case independently may backfire.

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel